A Phase II Extension of a Randomized, Open-Label, Multiple-Rising Dose Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Maintenance of Anemia Treatment in Patients with Chronic Kidney Disease who are on Hemodialysis.
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2013
Price : $35 *
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Merck & Co
- 12 Oct 2013 Planned number of patients changed to 150.
- 12 Oct 2013 New trial record